Endocrine Cocktails for Advanced Breast Cancer

Abstract

Prior studies have provided little evidence that combination endocrine therapy — for example, with tamoxifen plus older-generation aromatase inhibitors such as aminoglutethimide — improves outcomes over more common sequential endocrine therapy for patients with metastatic, hormone receptor–positive breast cancer. However, with the introduction of more-selective aromatase inhibitors (anastrozole, letrozole, and exemestane) and the novel estrogen-receptor agonist fulvestrant, the concept of combination endocrine therapy has been revisited. Investigators have now compared the efficacy of …